Search
EHA Statement on COVID-19
The European Hematology Association (EHA) closely monitors the latest developments on the spreading of the Coronavirus (COVID-19).
Read moreMolecular Hematopoiesis Workshop
The Molecular Hematopoiesis Workshop at the EHA2025 Congress is back!
OrganizersChair: Michael Milsom (Germany)
Co-chairs: Kim De Keersmaecker (Belgium), Elisa Laurenti (United Kingdom) & Britta Will (United States)
Submit your abstract for the workshop here
Program The workshop will take place on Thursday, June…
Pomalidomide prolongs survival in refractory myeloma patients
MM-003 is a large, multi-centre phase 3 study that assessed the efficacy and safety of a new drug, Pomalidomide (POM) in combination with low-dose dexamethasone (POM+LoDex) and compared this combination with high dose dexamethasone in MM patients with late stage…
Read moreChairs and Members
Chair (until 2026)Hermann Einsele, Professor of Hematology and Oncology, University Hospital Würzburg (Germany)
Co-chair (until 2026)Arjan van de Loosdrecht, Professor of Hematology and Immunhematology, Amsterdam UMC (The Netherlands)
SWG Steering Committee members
Jorge Sierra, Professor of Hematology, Hospital Santa Creu I Sant Pau…
Board elections
Shape the future of EHA by taking part in our 2025 Board election. Nominations closed on February 9, 2025. The ballot will open on April 8, 2025.
Read moreManage your membership
It's easy to amend your contact details or update your preferences. To get started, make sure you have your MyEHA log-in details. You can then follow the relevant steps below.
Read moreSWG Educational Activities
In 2021, the SWG on Multiple Myeloma contributed a major part of the ESMO-EHA guidelines for multiple myeloma. The rapid changes of the treatment landscape for this disease require an adaptation of the guidelines.
Read moreNew at EHA 15: EHA-JSH Joint Symposium
On behalf of JSH Dr Toshiki Watanabe will speak about "Molecular pathogenesis of ATL". Dr Herman Einsele presents EHA with his lecture "New treatments strategies for EBV-associated LPD as a model for immunotherapy of virus-associated/induced tumors".
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- 121
- 122
- 123
- 124
- 125
- 126
- 127
- 128
- 129
- 130
- 131
- 132
- 133
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- 141
- 142
- 143
- 144
- 145
- 146
- 147
- 148
- 149
- 150
- 151
- »